FDA Approves SITAGLIPTIN AND METFORMIN HYDROCHLORIDE — Zydus Lifesciences Limited
Zydus Lifesciences Limited received FDA approval for its combination tablet of sitagliptin and metformin hydrochloride, a move aimed at broadening accessibility for type 2 diabetes treatment as it faces increased market competition from United Therapeutics.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed